Pharma News

The latest developments from pharmaceutical and biopharmaceutical companies, both innovator and generic-drug companies, and leading regulatory news.

Bristol-Myers Squibb (BMS) has completed its $13.1-billion acquisition of MyoKardia, a Brisbane, California-based clinical-stage biopharmaceutical company focused on cardiovascular diseases. BMS had announced the acquisition last month (October...

Mylan and Pfizer have completed their previously announced combination of Mylan and Upjohn, Pfizer’s off-patent branded and generic established medicines business, to form a new company, Viatris. The companies had announced the merger in July...

Novo Nordisk has agreed to acquire Emisphere Technologies, a Roseland, New Jersey-based drug-delivery company, for $1.8 billion. Novo Nordisk and Emisphere have collaborated since 2007. Emisphere’s drug-delivery technology, Eligen SNAC, is used by...

Endo International, a generics and specialty branded pharmaceuticals company, has announced it is reducing staff by 560 and exiting some manufacturing sites. To improve its cost structure in its generics business, Endo is exiting manufacturing...

Mylan and Pfizer have received final approval from the US Federal Trade Commission for their proposed combination of Mylan and Upjohn, Pfizer’s off-patent branded and generic established medicines business. The companies had announced the planned...

Pfizer has announced it will make a EUR 300-million ($351-million) capital investment in its Irish operations to support the further development of its existing manufacturing sites in Grange Castle, Newbridge, and Ringaskiddy. The investment will...

Sanofi has agreed to acquire Kiadis Pharma, an Amsterdam-based clinical-stage company developing therapeutics based on natural killer (NK) cells, for EUR 308 million ($358 million). Kiadis’ proprietary platform is based on allogeneic or...